|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07C 229/50 | |
| A61P 25/24 | |||
| A61K 31/21 |
| (11) | Number of the document | 2640687 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11793573.4 |
| Date of filing the European patent application | 2011-11-15 | |
| (97) | Date of publication of the European application | 2013-09-25 |
| (45) | Date of publication and mention of the grant of the patent | 2018-06-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/060686 |
| Date | 2011-11-15 |
| (87) | Number | WO 2012/068041 |
| Date | 2012-05-24 |
| (30) | Number | Date | Country code |
| 415113 P | 2010-11-18 | US |
| (72) |
DRESSMAN, Bruce Anthony, US
CHAPPELL, Mark Donald, US
FIVUSH, Adam Michael, US
MITCH, Charles Howard, US
ORNSTEIN, Paul Leslie, US
TROMICZAK, Eric George, US
VETMAN, Tatiana Natali, US
|
| (73) |
Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
| 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |